Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Sweet, Kendra  [Clear All Filters]
2024
Ionescu F, David JC, Ravichandran A, Sallman DA, Sweet K, Komrokji RS, Chan O, Kuykendall A, Padron E, Faramand R, et al. Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk. 2024.
2023
Jain A, Sweet K. Blastic Plasmacytoid Dendritic Cell Neoplasm. J Natl Compr Canc Netw. 2023;21(5):515-521.
Patel PC, Ball S, Jain AG, Wang C, Hussaini MO, Aguirre LE, Chan O, Yun S, Kuykendall A, Padron E, et al. Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia. Am J Hematol. 2023.
Jain AG, Ball S, Aguirre LE, Tobon KA, Chan O, Padron E, Kuykendall A, Komrokji R, Sallman D, Lancet JE, et al. Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2023.
2020
Chan O, Talati C, Isenalumhe L, Shams S, Nodzon L, Fradley M, Sweet K, Pinilla-Ibarz J. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Adv. 2020;4(3):530-538.
2019
Chan O, Talati C, Sweet K, Pinilla-Ibarz J. Can increased immunogenicity in chronic myeloid leukemia improve outcomes?. Expert Rev Hematol. 2019:1-9.
2018
Sweet K, Hazlehurst L, Sahakian E, Powers J, Nodzon L, Kayali F, Hyland K, Nelson A, Pinilla-Ibarz J. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leuk Res. 2018;74:89-96.
Talati C, Sweet K. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape. Leuk Res. 2018;73:58-66.